BridgeBio Pharma Inc
BBIOHealthcare|Biotechnology|USA
$85.81
-4.28 (-4.75%)
Financials
Financial Snapshot
Market Cap
$16.81B
Enterprise Value
$-1.56B
Revenue (TTM)
$580.0M
Net Income (TTM)
$-721.6M
Cash & Equivalents
—
Net Cash/Share
$-13.84
Free Cash Flow (TTM)
$-452.0M
Operating CF (TTM)
$-444.0M
Debt/Equity
-1.09
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$111.0M
Monthly Burn
$37.0M
Est. Runway
—
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $92.0M | $436.1M | $546.0M | $607.1M | $836.7M | $471.9M | $434.9M | $681.1M | $587.5M | $940.2M | |
| Operating Cash Flow | $-40.5M | $-136.6M | $-253.6M | $-399.7M | $-497.9M | $-419.5M | $-527.7M | $-520.7M | $-445.9M | $-444.0M | |
| Free Cash Flow | $-41.0M | $-154.8M | $-256.2M | $-407.2M | $-546.2M | $-425.8M | $-529.0M | $-529.6M | $-455.5M | $-452.0M | |
| Capital Expenditure | $-464.0K | $-18.2M | $-2.6M | $-7.5M | $-48.2M | $-6.3M | $-1.3M | $-8.9M | $-9.6M | $-8.1M | |
| Financing Cash Flow | $113.0M | $501.5M | $398.8M | $447.2M | $736.4M | $-13.1M | $451.5M | $748.5M | $359.3M | $848.9M |
R&D Spending
R&D (TTM)
$467.2M
R&D Intensity
80.6%
R&D Growth YoY
+3.4%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $40.6M | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M | $580.0M | |
| R&D Expense | $30.6M | $140.1M | $209.9M | $337.0M | $451.0M | $399.5M | $455.7M | $506.5M | $452.0M | $467.2M | |
| R&D % of Revenue | — | — | 517.6% | 4085.9% | 646.9% | 514.5% | 4898.5% | 228.2% | 90.0% | 80.6% | |
| SG&A | $13.3M | $43.6M | $94.4M | $145.7M | $192.2M | $143.2M | $150.6M | $288.9M | $531.2M | $588.8M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $40.6M | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M | $580.0M | |
| Cost of Goods Sold | $0.00 | $0.00 | $2.5M | $0.00 | $3.1M | $3.4M | $2.4M | $3.9M | $21.0M | $28.3M | |
| Gross Profit | $0.00 | $0.00 | $38.1M | $8.2M | $66.6M | $74.2M | $6.9M | $218.0M | $481.1M | $551.7M | |
| R&D | $30.6M | $140.1M | $209.9M | $337.0M | $451.0M | $399.5M | $455.7M | $506.5M | $452.0M | $467.2M | |
| SG&A | $13.3M | $43.6M | $94.4M | $145.7M | $192.2M | $143.2M | $150.6M | $288.9M | $531.2M | $588.8M | |
| Operating Income | $-43.9M | $-183.7M | $-266.2M | $-474.5M | $-576.6M | $-468.4M | $-599.4M | $-577.4M | $-502.1M | $-504.2M | |
| Interest Expense | $-13.0K | $-2.5M | $-8.8M | $-36.7M | $-46.8M | $-80.4M | $-81.3M | $-99.3M | $-178.2M | $-188.9M | |
| Pretax Income | $-43.8M | $-169.5M | $-288.6M | $-505.5M | $-586.5M | $-484.7M | $-653.3M | $-542.2M | $-732.5M | $-729.5M | |
| Net Income | $-30.6M | $-130.7M | $-260.6M | $-448.7M | $-562.5M | $-481.2M | $-643.2M | $-535.8M | $-724.9M | $-721.6M | |
| EPS (Diluted) | -0.33 | -1.42 | -2.48 | -3.80 | -3.90 | -3.26 | -3.95 | -2.88 | -3.78 | -3.74 | |
| EBITDA | $-43.8M | $-166.9M | $-279.0M | $-467.4M | $-533.8M | $-397.4M | $-565.5M | $-436.8M | $-548.8M | $-535.2M | |
| Shares Out. (M) | 92.33 | 92.33 | 105.10 | 118.00 | 144.36 | 147.47 | 162.79 | 186.08 | 191.53 | 194.79 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $92.0M | $436.1M | $363.8M | $356.1M | $393.8M | $376.7M | $375.9M | $681.1M | $570.1M | $879.9M | |
| Marketable Securities | $0.00 | $0.00 | $182.2M | $251.0M | $442.9M | $95.2M | $58.9M | $0.00 | $17.4M | $60.3M | |
| Total Current Assets | $97.1M | $445.2M | $568.6M | $642.8M | $888.9M | $548.9M | $477.6M | $720.7M | $797.7M | $1.24B | |
| Total Assets | $98.0M | $464.9M | $631.7M | $703.6M | $1.01B | $623.0M | $546.4M | $919.3M | $936.0M | $1.37B | |
| Total Current Liabilities | $8.6M | $32.6M | $60.4M | $95.6M | $135.1M | $121.4M | $143.8M | $154.4M | $288.0M | $816.4M | |
| Long-Term Debt | $0.00 | $54.5M | $91.8M | $475.9M | $1.70B | $1.71B | $1.73B | $1.72B | $1.85B | $1.93B | |
| Total Liabilities | $152.7M | $87.6M | $155.7M | $595.7M | $1.88B | $1.87B | $1.89B | $2.38B | $3.01B | $3.64B | |
| Stockholders' Equity | $-58.0M | $314.9M | $408.5M | $57.9M | $-870.4M | $-1.25B | $-1.35B | $-1.47B | $-2.09B | $-2.28B | |
| Retained Earnings | $-61.4M | $-179.4M | $-440.0M | $-888.8M | $-1.44B | $-1.92B | $-2.56B | $-3.10B | $-3.82B | $-3.99B |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $-40.5M | $-136.6M | $-253.6M | $-399.7M | $-497.9M | $-419.5M | $-527.7M | $-520.7M | $-445.9M | $-444.0M | |
| Capital Expenditure | $-464.0K | $-18.2M | $-2.6M | $-7.5M | $-48.2M | $-6.3M | $-1.3M | $-8.9M | $-9.6M | $-8.1M | |
| Free Cash Flow | $-41.0M | $-154.8M | $-256.2M | $-407.2M | $-546.2M | $-425.8M | $-529.0M | $-529.6M | $-455.5M | $-452.0M | |
| Investing Cash Flow | $-464.0K | $-21.0M | $-217.3M | $-53.0M | $-200.8M | $453.1M | $54.0M | $60.8M | $-24.5M | $-65.6M | |
| Financing Cash Flow | $113.0M | $501.5M | $398.8M | $447.2M | $736.4M | $-13.1M | $451.5M | $748.5M | $359.3M | $848.9M | |
| Issuance of Stock | $0.00 | $95.5M | $366.2M | $0.00 | $0.00 | $4.9M | $449.8M | $314.7M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $-75.7M | $-204.7M | $-1.6M | $-6.9M | $-7.5M | $-62.5M | $-99.0M | |
| Issuance of Debt | $4.1M | $57.5M | $36.9M | $550.0M | $1.20B | $0.00 | $0.00 | $450.0M | $575.0M | $632.5M | |
| Payments of Debt | $0.00 | $-1.1M | $0.00 | $0.00 | $-124.1M | $-20.5M | $0.00 | $-473.4M | $-459.0M | $0.00 | |
| Stock Based Comp. | $1.8M | $6.1M | $21.4M | $58.5M | $99.5M | $91.6M | $108.7M | $95.8M | $133.0M | $140.4M | |
| Net Change in Cash | $72.0M | $343.9M | $-72.0M | $-5.5M | $37.7M | $20.5M | $-22.2M | $288.5M | $-111.1M | $339.3M |
Dilution Tracker
Shares outstanding grew 34.9% over 5 years — significant dilution
Shares Outstanding
195M
5-Year Share Growth
+34.9%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 92.33 | 92.33 | 105.10 | 118.00 | 144.36 | 147.47 | 162.79 | 186.08 | 191.53 | 194.79 | |
| YoY Change % | — | 0.0% | 13.8% | 12.3% | 22.3% | 2.2% | 10.4% | 14.3% | 2.9% | 1.7% | |
| Stock Issuance | $0.00 | $95.5M | $366.2M | $0.00 | $0.00 | $4.9M | $449.8M | $314.7M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $-75.7M | $-204.7M | $-1.6M | $-6.9M | $-7.5M | $-62.5M | $-99.0M | |
| Stock Based Comp. | $1.8M | $6.1M | $21.4M | $58.5M | $99.5M | $91.6M | $108.7M | $95.8M | $133.0M | $140.4M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 93.8% | 0.0% | 95.5% | 95.6% | 73.7% | 98.3% | 95.8% | 95.1% | |
| Operating Margin % | 0.0% | 0.0% | -656.4% | -5752.0% | -827.1% | -603.3% | -6443.6% | -260.2% | -100.0% | -86.9% | |
| Net Margin % | 0.0% | 0.0% | -642.5% | -5439.7% | -806.9% | -619.7% | -6913.9% | -241.4% | -144.4% | -124.4% | |
| EBITDA Margin % | 0.0% | 0.0% | -687.8% | -5665.9% | -765.7% | -511.9% | -6078.3% | -196.9% | -109.3% | -92.3% | |
| FCF Margin % | 0.0% | 0.0% | -631.7% | -4936.7% | -783.4% | -548.4% | -5686.6% | -238.7% | -90.7% | -77.9% | |
| ROE % | 0.0% | -101.8% | -72.1% | -192.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROA % | -31.2% | -46.4% | -47.5% | -67.2% | -65.5% | -58.8% | -110.0% | -73.1% | -78.1% | -68.5% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.41
P/S28.57
Historical12.57 / 40.74 / 1015.86
Industry Med.9.51
P/B—
Historical4.65 / 12.05 / 150.98
Industry Med.2.93
EV/EBITDA-34.32
Historical-34.32 / -13.53 / -3.66
Industry Med.13.14
EV/Revenue31.67
Historical24.90 / 46.75 / 1213.72
Industry Med.8.71
P/FCF—
Historical— / — / —
Industry Med.27.54
Intrinsic Value Models
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | 90.80 | 1015.86 | 34.53 | 14.46 | 708.25 | 23.00 | 29.18 | 28.57 | |
| PB Ratio | 0.00 | 0.00 | 10.61 | 150.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EV/EBITDA | 0.00 | 0.00 | -14.15 | -18.56 | -6.28 | -6.06 | -14.83 | -14.36 | -29.49 | -34.32 | |
| EV/Revenue | 0.00 | 0.00 | 97.33 | 1051.58 | 48.08 | 31.03 | 901.30 | 28.28 | 32.23 | 31.67 |
Analyst Estimates & Quality
Altman Z-Score
-1.81
Distress
Piotroski F-Score
3
Weak
Beneish M-Score
-0.66
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $975.3M | $1,636.9M | $2,404.0M |
| Net Income | $-437.9M | $136.6M | $828.0M |
| EPS | -2.03 | 0.61 | 3.79 |
| Book Value per Share | -12.37 | -8.62 | -1.31 |
| Operating Cash Flow per Share | -1.95 | 1.76 | 0.00 |
| Operating CF | $-379.84M | $342.83M | $0.00M |
Dividends
Revenue Segments
By Business
| Segment | 2025 |
|---|---|
| Identifying, advancing and commercializing transformative medicines to treat patients | $502.1M |
By Geography
| Segment | 2025 |
|---|---|
| United States | $362.5M |
| Asia-Pacific (APAC) | $12.6M |
| Europe, Middle East, and Africa (EMEA) | $127.0M |